Search | Clinical Trials Finder

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Dermatitis, Atopic
Interventions: GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Fort Smith, Arkansas • Fresno, California • Irvine, California + 30 more

Conditions: Atopic Dermatitis
Interventions: Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more

Conditions: Atopic Dermatitis (AD)
Interventions: Experimental Product; Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 6 Months and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: St. Petersburg, Florida • Fair Lawn, New Jersey

Conditions: Atopic Dermatitis
Interventions: KP-413 Ointment; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: SRD174 Cream, vehicle cream; Drug · Other
Lead sponsor: Serentis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 12 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Atopic Dermatitis
Interventions: ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more

Conditions: Atopic Dermatitis (AD)
Interventions: Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2; Drug
Lead sponsor: Daniel Kaplan; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Interventions: HY209GEL Active, Placebo; Drug · Other
Lead sponsor: Shaperon; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 4 more

Conditions: Atopic Dermatitis
Interventions: DS107, Vehicle cream; Drug · Other
Lead sponsor: DS Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more

Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 72
States / cities: Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more

Conditions: Atopic Dermatitis
Interventions: LEO 138559, LEO 138559 placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 2 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 69
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 58 more

Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Interventions: Lutikizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Ann Arbor, Michigan

Conditions: Atopic Dermatitis (AD), Asthma
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Atopic Dermatitis
Interventions: BBT001, Placebo; Drug
Lead sponsor: Bambusa Therapeutics; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Irvine, California • New York, New York • The Bronx, New York

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab Prefilled Syringe, Rocatinlimab AI; Combination Product
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Atopic Dermatitis
Interventions: ZPL389 30mg, ZPL389 50mg, TCS and/or TCI; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Litchfield Park, Arizona • Fairborn, Ohio

Conditions: Atopic Dermatitis
Interventions: ILV-094, Placebo Comparator; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 58
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more

Conditions: Atopic Dermatitis
Interventions: Locoid Lipocream, Hylatopic Plus; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 3 Months and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream